Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Online Access: | http://dx.doi.org/10.1186/s40545-020-00274-8 |
| _version_ | 1797401315467329536 |
|---|---|
| author | Ali Elbeddini Rachel Gerochi Ahmed Elshahawi |
| author_facet | Ali Elbeddini Rachel Gerochi Ahmed Elshahawi |
| author_sort | Ali Elbeddini |
| collection | DOAJ |
| description | Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathies |
| first_indexed | 2024-03-09T02:08:19Z |
| format | Article |
| id | doaj.art-f06c18aaf47341b185b59922a1e1a903 |
| institution | Directory Open Access Journal |
| issn | 2052-3211 |
| language | English |
| last_indexed | 2024-03-09T02:08:19Z |
| publishDate | 2020-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj.art-f06c18aaf47341b185b59922a1e1a9032023-12-07T15:28:03ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112020-12-0113110.1186/s40545-020-00274-812315197Evaluation of the prophylaxis and treatment of COVID-associated coagulopathyAli Elbeddini0Rachel Gerochi1Ahmed Elshahawi2Winchester District Memorial Hospital,Leslie Dan Faculty of Pharmacy,University of Toronto Medical School,Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathieshttp://dx.doi.org/10.1186/s40545-020-00274-8 |
| spellingShingle | Ali Elbeddini Rachel Gerochi Ahmed Elshahawi Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy Journal of Pharmaceutical Policy and Practice |
| title | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
| title_full | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
| title_fullStr | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
| title_full_unstemmed | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
| title_short | Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy |
| title_sort | evaluation of the prophylaxis and treatment of covid associated coagulopathy |
| url | http://dx.doi.org/10.1186/s40545-020-00274-8 |
| work_keys_str_mv | AT alielbeddini evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy AT rachelgerochi evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy AT ahmedelshahawi evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy |